Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor
Austin Clyde, Stephanie Galanie, Daniel W. Kneller, et al.
Journal of Chemical Information and Modeling (2021) Vol. 62, Iss. 1, pp. 116-128
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
Daniel W. Kneller, Hui Li, G.N. Phillips, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 96
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 51
Molecular Glue Discovery: Current and Future Approaches
Jeffrey A. Dewey, Clémence Delalande, Saara‐Anne Azizi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9278-9296
Open Access | Times Cited: 44
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity
Shenghua Gao, Katharina Sylvester, Letian Song, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13343-13364
Closed Access | Times Cited: 63
Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits
Giacomo G. Rossetti, Marianna Ossorio, S. Rempel, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 59
#COVIDisAirborne: AI-enabled multiscale computational microscopy of delta SARS-CoV-2 in a respiratory aerosol
Abigail C. Dommer, Lorenzo Casalino, Fiona L. Kearns, et al.
The International Journal of High Performance Computing Applications (2022) Vol. 37, Iss. 1, pp. 28-44
Open Access | Times Cited: 59
Qualitative Estimation of Protein–Ligand Complex Stability through Thermal Titration Molecular Dynamics Simulations
Matteo Pavan, Silvia Menin, Davide Bassani, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 22, pp. 5715-5728
Open Access | Times Cited: 39
Structural biology of SARS-CoV-2 Mpro and drug discovery
Yinkai Duan, Haofeng Wang, Zhenghong Yuan, et al.
Current Opinion in Structural Biology (2023) Vol. 82, pp. 102667-102667
Closed Access | Times Cited: 22
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 22
Thermal Titration Molecular Dynamics (TTMD): Not Your Usual Post-Docking Refinement
Silvia Menin, Matteo Pavan, Veronica Salmaso, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3596-3596
Open Access | Times Cited: 21
Neoechinulin A as a Promising SARS-CoV-2 Mpro Inhibitor: In Vitro and In Silico Study Showing the Ability of Simulations in Discerning Active from Inactive Enzyme Inhibitors
Hani A. Alhadrami, Gaia Burgio, Bathini Thissera, et al.
Marine Drugs (2022) Vol. 20, Iss. 3, pp. 163-163
Open Access | Times Cited: 28
Large library docking for novel SARS‐CoV‐2 main protease non‐covalent and covalent inhibitors
Elissa A. Fink, Conner Bardine, Stefan Gahbauer, et al.
Protein Science (2023) Vol. 32, Iss. 8
Open Access | Times Cited: 20
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 19
AI-accelerated protein-ligand docking for SARS-CoV-2 is 100-fold faster with no significant change in detection
Austin Clyde, Xuefeng Liu, Thomas Brettin, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 17
On the origins of SARS-CoV-2 main protease inhibitors
Yves L. Janin
RSC Medicinal Chemistry (2023) Vol. 15, Iss. 1, pp. 81-118
Closed Access | Times Cited: 15
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 5
Computational evaluation and benchmark study of 342 crystallographic holo-structures of SARS-CoV-2 Mpro enzyme
Hamlet Khachatryan, Mher Matevosyan, Vardan Harutyunyan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Thermal Titration Molecular Dynamics: The Revenge of the Fragments
Matteo Pavan, Silvia Menin, Andrea Dodaro, et al.
Journal of Chemical Information and Modeling (2025)
Open Access
Discovery of TRPV4-Targeting Small Molecules with Anti-Influenza Effects Through Machine Learning and Experimental Validation
Yan Sun, Jiajing Wu, Beilei Shen, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1381-1381
Open Access
Identifying Inhibitor-SARS-CoV2-3CLpro Binding Mechanism Through Molecular Docking, GaMD Simulations, Correlation Network Analysis and MM-GBSA Calculations
Jianzhong Chen, Jian Wang, Wanchun Yang, et al.
Molecules (2025) Vol. 30, Iss. 4, pp. 805-805
Open Access
Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease
Daniel W. Kneller, Hui Li, Stephanie Galanie, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 23, pp. 17366-17383
Open Access | Times Cited: 38
Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020
Roufen Chen, Yali Gao, Han Liu, et al.
RSC Medicinal Chemistry (2022) Vol. 14, Iss. 1, pp. 9-21
Open Access | Times Cited: 25
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors
Shenghua Gao, Letian Song, Tobias Claff, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16902-16917
Closed Access | Times Cited: 25
Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor
Jens Gläser, Ada Sedova, Stephanie Galanie, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 4, pp. 255-265
Open Access | Times Cited: 24
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
Kirsten McAulay, Alan Bilsland, Marta Bon
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1366-1366
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top